CollPlant Biotechnologies (CLGN) Operating Income (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly Operating Income came in at -$3.1 million in Q1 2026, down 89.02% YoY from -$28.4 million in Q1 2025, and up 1.11% on a QoQ basis from -$3.2 million in Q4 2025.
CollPlant Biotechnologies (CLGN) Operating Income (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of Operating Income data on file, last reported at -$3.1 million in Q1 2026.
- Quarterly Operating Income fell 89.02% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.6 million (down 14.52% YoY) and the FY2025 annual result came in at -$11.5 million, up 33.44% from the prior year.
- Operating Income climbed to -$3.1 million in Q1 2026, from -$3.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $5.7 million in Q2 2023 to a low of -$5.1 million in Q4 2023.
- A 5-year average of -$1.1 million and a median of -$3.2 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income surged 235.65% — and 2025, when it plunged 138.07%.
- Tracing CLGN's Operating Income over 5 years: stood at -$4.7 million in 2022, then fell by 8.38% to -$5.1 million in 2023, then climbed by 21.59% to -$4.0 million in 2024, then grew by 20.73% to -$3.2 million in 2025, then increased by 1.11% to -$3.1 million in 2026.
- The last three Operating Income figures came in at -$3.1 million (Q1 2026), -$3.2 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | -3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -3.12 Mn |
| Dec 31, 2025 | -3.15 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 30, 2025 | -1.65 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | -5.07 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | 5.68 Mn |
| Mar 31, 2023 | 3.52 Mn |
| Dec 31, 2022 | -4.68 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -4.19 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | -3.80 Mn |
| Sep 30, 2021 | -3.09 Mn |
| Jun 30, 2021 | -3.06 Mn |